Exclusion Criteria:~* Significant neurological disease affecting the central nervous system (other than AD),
that may affect cognition or ability to complete the study, including but not limited to, other dementias,
serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack
or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures).~* Current serious or unstable
medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic,
psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse),
immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could
interfere with the analyses in this study; or has a life expectancy of approximately~ ≤24 months.~* History of
clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
(including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal
necrolysis, and/or exfoliative dermatitis).~* History of bleeding disorder or use of medications with platelet
anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg).~* Have had prior or current
treatment with donanemab or aducanumab~* Have known allergies to donanemab or aducanumab, related compounds, or
any components of the formulation~* Prior or current participation in any immunotherapy study targeting Amyloid
beta
